¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"equipment failure analysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cost-benefit analysis
    ºñ¿ëÆíÀͺм®
  • cost-effectiveness analysis
    ºñ¿ëÈ¿°úºÐ¼®
  • cost-efficiency analysis
    ºñ¿ëÈ¿À²ºÐ¼®
  • cost-utility analysis
    ºñ¿ëÈ¿¿ëºÐ¼®
  • case analysis
    »ç·ÊºÐ¼®, Áõ·ÊºÐ¼®
  • decision analysis
    ÀÇ»ç°áÁ¤ºÐ¼®
  • discriminant analysis
    ÆÇº°ºÐ¼®
  • distributive analysis
    ºÐÆ÷ºÐ¼®
  • gastric analysis
    À§¾×°Ë»ç
  • gene analysis
    À¯ÀüÀںм®
  • image analysis
    ¿µ»óºÐ¼®
  • Kaplan-Meier analysis
    Ä«Çöõ-¸¶À̾îºÐ¼®
  • linkage analysis
    ¿¬°üºÐ¼®
  • multipoint linkage analysis
    ´ÙÁ¡¿¬°üºÐ¼®
  • multivariate analysis
    ´Ùº¯·®ºÐ¼®, ´Ù¿äÀκм®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • distributive analysis
    ºÐÆ÷ºÐ¼®
  • gene analysis
    À¯ÀüÀںм®
  • image analysis
    ¿µ»óºÐ¼®
  • multivariate analysis
    ´Ùº¯·®ºÐ¼®, ´Ù¿äÀκм®
  • nephelometric analysis
    ȥŹºÐ¼®
  • path analysis
    °æ·ÎºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®
  • principal component analysis
    ÁÖ¼ººÐºÐ¼®
  • process analysis
    °øÁ¤ºÐ¼®, °úÁ¤ºÐ¼®
  • qualitative analysis
    Á¤¼ººÐ¼®
  • quantitative analysis
    Á¤·®ºÐ¼®
  • radiochemical analysis
    ¹æ»çÈ­Çкм®
  • radiometric analysis
    ¹æ»ç¼±ºÐ¼®
  • regression analysis
    Èֱͺм®
  • risk benefit analysis
    À§ÇèÆíÀͺм®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • immunoglobulin subgroup analysis
    ¸é¿ª±Û·ÎºÒ¸°¾ÆÇüºÐ¼®
  • indirect analysis
    °£Á¢ºÐ¼®.
  • infrared spectroscopic analysis
    Àû¿Ü¼± ºÐ±¤ ºÐ¼®
  • inorganic analysis
    ¹«±âºÐ¼®(¡­ÝÂà°).
  • plasma analysis
    Ç÷ÀåºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®(ÊÙËÓËÛ).
  • precipitation analysis =p. titration
    ħÀüºÐ¼®.
  • predictive analysis
    È¿°ú¿¹ÃøºÐ¼®
  • process analysis
    °øÁ¤ºÐ¼®(Ë­ËøËÓËÛ).
  • qualitative analysis
    Á¤¼ººÐ¼®(ïÒàõÝÂà°).
  • quantitative analysis
    Á¤·®ºÐ¼®(ïÒåÖÝÂà°).
  • radiometric analysis
    ¹æ»ç¼± ºÐ¼®
  • radiometric analysis
    ¹æ»çÃøÁ¤ºÐ¼®
  • rational analysis
    ½Ã¼ººÐ¼®(ãÆàõÝÂà°).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • failure to thrive
    ¼ºÀå½ÇÆÐ<Áß´Ü> (à÷íþã÷ø¨<ñéÓ¨>)
  • forward failure
    Àü¹æºÎÀü(îñÛ°ÝÕîï).
  • forward failure
    ÀüÁø¼º½ÇÆÐ
  • forward heart failure
    Àü¹æ½ÉºÎÀü.
  • fusion failure
    À¶ÇÕºÎÀü
  • groth failure
  • growth failure
    ¼ºÀåºÎÀü(à÷íþÝÕîï).
  • heart failure
    ½ÉºÎÀü(ãýÝÕîï).
  • heart failure cell
    ½ÉºÎÀü¼¼Æ÷(¡­á¬øà)
  • hepatic failure
    °£ºÎÀü(°£ºÒÀü).
  • hepatic failure
    °£ºÎÀü(ÊÜÝÕîï).
  • hepatic failure
    °£ºÎÀü(ÊÜÜôîï)
  • high output failure
    °í¹ÚÃ⼺ ½ÉºÎÀü.
  • high output heart failure
    °í¹ÚÃ⼺ ½ÉºÎÀü(ÍÔÚÐõóàõãýÝÕîï).
  • hypodiastolic failure
    ÀúÈ®Àå±â¼º ½ÉºÎÀü.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ECIS equipment control information system
ECN equipment control number
equip equipment
ESR Einstein stoke radius; electric skin resistance; electron spin resonance; equipment service report; ...
HELP Hawaii early learning profile; Health Education Library Program; Health Emergency Loan Program; Heal...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
FPT Failure of passive transfer
FTT Failure to Thrive
FFS Failure-free survival
FFTF Freedom-from-treatment-failure
FHF Fulminant Hepatic Failure
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • elementary analysis
    ¿ø¼Ò ºÐ¼®
    À¯±â È­ÇÕ¹°¿¡ ÇÔÀ¯µÇ¾î ÀÖ´Â ¿ø¼ÒÀÇ Á¾·ù¸¦ °áÁ¤Çϰųª, ºñÀ²À» °áÁ¤ÇÏ´Â ºÐ¼® ¹æ¹ý. ÀüÀÚ¸¦ Á¤¼º ¿ø¼Ò ºÐ¼®, ÈÄÀÚ¸¦ Á¤·® ¿ø¼Ò ºÐ¼®À̶ó°í ÇÑ´Ù. Á¤¼º ¿ø¼Ò ºÐ¼®, Áï ¿ø¼Ò °ËÃâ¹ý¿¡¼­´Â À¯±â È­ÇÕ¹°À» ±¸¼ºÇϰí ÀÖ´Â °¢ ¿ø¼Ò¿¡ µû¶ó ¿©·¯ °¡Áö ¹æ¹ýÀÌ »ç¿ëµÇÁö¸¸, ¸ðµÎ À¯±â È­ÇÕ¹°À» ºÐÇØÇÏ¿© °£´ÜÇÑ ¹«±â È­ÇÕ¹°·Î °ËÃâÇÑ´Ù. Á¤·® ¿ø¼Ò ºÐ¼®, Áï ÇÔÀ¯·®À» °áÁ¤ÇÏ´Â ¹æ¹ý¿¡´Â äÃëÇÏ´Â ½Ã·áÀÇ ¾ç¿¡ µû¶ó¼­ »ó·®¹ý
  • Enlow Analysis
    ¿£·Î¿ì ºÐ¼®
  • frequency analysis
    ÁÖÆÄ ¼ö ºÐ¼®
  • in vivo analysis
    »ýü³» ºÐ¼®
  • infrared spectroscopic analysis
    Àû¿Ü¼± ºÐ±¤ ºÐ¼®
  • inorganic analysis
    ¹«±â ºÐ¼®
  • laboratory analysis
    ½ÇÇè½Ç ºÐ¼®
  • mixed dentition analysis
    È¥ÇÕ Ä¡¿­±âÀÇ ¾Ç±Ã °ø°£ ºÐ¼®
    È¥ÇÕ Ä¡¿­±â ±³ÇÕÀº ¿µ±¸ Á¦1 ´ë±¸Ä¡°¡ ¸ÍÃâÇÏ´Â 6-7¼¼ºÎÅÍ Çü¼ºµÈ´Ù. ½ÃÁø ¹× ±¸°­ ¹æ»ç¼±ÇÐÀû °Ë»çÀÇ È°¿ëÀ» ÅëÇØ ¿µ±¸Ä¡ ¸ÍÃâ ¼ø¼­¸¦ »ìÆìº¸´Â °ÍÀº Á¤»ó ±³ÇÕ Çü¼ºÀÇ °¡´É¼º ÆÇ´Ü¿¡ À¯È¿ÇÑ Á¤º¸¸¦ Á¦°øÇØ ÁØ´Ù.
  • occlusal analysis
    ±³ÇÕ ºÐ¼®
    ±³Çձ⿡ ÀåÂøµÈ ¸ðÇüÀÇ ±³ÇÕ °ü°è¸¦ Æò°¡ÇÏ´Â ±³ÇÕ.
  • qualitative analysis
    Á¤¼º ºÐ¼®
    È­ÇÐ ºÐ¼®¹ý Áß¿¡¼­ ½Ã·á°¡ ¾î¶² ¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´ÂÁö ¾Ë¾Æ³»±â À§ÇÑ ºÐ¼®¹ýÀÇ ÃÑĪ. ÀϹÝÀûÀ¸·Î Á¤·® ºÐ¼®À» Çϱâ Àü¿¡ Á¤¼º ºÐ¼®À» ÇÏ°Ô µÈ´Ù. ¹°ÁúÀ» ±¸¼ºÇϰí ÀÖ´Â È­ÇÐÁ¾
  • script analysis
    °¢º» ºÐ¼®
    »çȸ¿¡ Âü¿©ÇÒ ¶§ Çൿ ¾ç»óÀÇ Æ²ÀÎ °¢º»ÀÌ ¸¸µé¾îÁö´Â °úÁ¤¿¡ ´ëÇÑ ºÐ¼®.
  • sequential analysis
    ¼øÂ÷Àû ºÐ¼®
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • space analysis
    °ø°£ ºÐ¼®
  • spectral analysis
    ½ºÆåÆ®·³ ºÐ¼®
    ¹°ÁúÀÇ ¹æÃâ ½ºÆåÆ®·³ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¶»çÇÏ¿©, ±× ¼Ó¿¡ ÀÖ´Â ¼ººÐ ¿ø¼Ò³ª È­ÇÕ¹°ÀÇ Á¾·ù¿Í ¾çÀ» ÆÇÁ¤ÇÏ´Â ¹æ¹ý. ºÐ±¤ È­ÇÐ ºÐ¼®À̶ó°íµµ ÇÑ´Ù. 19¼¼±â Áß¿±¿¡ R. ºÐÁ¨ÀÌ G. ۸£È÷È£ÇÁÀÇ Çù·ÂÀ» ¾ò¾î È®¸³½ÃŲ ½ÇÇè ±â¼úÀ̸ç, º¸ÅëÀÇ È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© Á¶ÀÛÀÌ ºü¸£°í, ¼Ò·®ÀÇ ½Ã·á·Îµµ ºÐ¼®ÀÌ °¡´ÉÇÑ ÀÌÁ¡ÀÌ ÀÖ´Ù. ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °Í°ú, Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ °ÍÀÇ µÎ °¡Áö·Î Å©°Ô ³ª´­ ¼ö ÀÖ´Ù. ¡¼¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ¿øÀÚ¿¡¼­ ¹æÃâµÇ´Â ºûÀÇ ½ºÆåÆ®·³ÀÌ °¢ ¿ø¼Ò¿¡ µû¶ó °íÀ¯ÇÔÀ» ÀÌ¿ëÇÔÀ¸·Î½á, ½Ã·á¸¦ ¹ß±¤½ÃÄÑ ½ºÆåÆ®·³À» °Ë»çÇϰí, ¹Ì¸® Á¶»çÇÏ¿© µÐ Ç¥ÁØ ½Ã·áÀÇ ¹æÃâ ½ºÆåÆ®·³À» ±âÃÊ·Î ¼ººÐ ¿ø¼ÒÀÇ Á¾·ù³ª ¾çÀ» ¾Ë¾Æ³»´Â ¹æ¹ýÀÌ´Ù. °ËÃâÀÇ Á¤¹Ðµµ´Â ¿ø¼Ò¿¡ µû¶ó ´Ù¸£Áö¸¸, ÀϹÝÀûÀ¸·Î È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© °¨µµ°¡ ³ô°í, ƯÈ÷ ±Ý¼Ó¿¡ ¹Ì·®À¸·Î ÇÔÀ¯µÇ¾î ÀÖ´Â ºÒ¼ø¹° ¿ø¼ÒÀÇ ¹ß°ßÀ̳ª Á¤·® µî¿¡´Â ÁÁÀº °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù. ½Ã·á¸¦ ¹ß±¤½ÃŰ´Â µ¥´Â º¸Åë ½Ã·á¸¦ ÇÑÂÊ ±ØÀ¸·Î ÇÏ´Â ¾ÆÅ© ¹æÀüÀ̳ª, ±âü »óÅÂÀÇ ½Ã·á¸¦ ¹æÀü°ü¿¡ ä¿ö¼­ ¹æÀü½ÃŰ´Â ¹æ¹ýÀÌ ÀÌ¿ëµÈ´Ù. ¾ËÄ®¸® ±Ý¼ÓÀ̳ª ¾ËÄ®¸®Åä ±Ý¼Ó¿¡ ´ëÇÑ ºÒ²É ¹ÝÀÀÀ» ÀÌ¿ëÇÑ ºÒ²É ½ÃÇèµµ ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °£´ÜÇÑ ºÐ±¤ ºÐ¼®À̶ó ÇÒ ¼ö ÀÖ´Ù. ¡¼Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ±âü³ª ¿ë¾×¿¡ ¿¬¼Ó ½ºÆåÆ®·³À» °¡Áø ºûÀ» Á¶»çÇϸé, ±× ¼Ó¿¡ Á¸ÀçÇϴ Ȭ ¿ø¼ÒÁúÀ̳ª È­ÇÕ¹°ÀÌ °¢°¢ ƯÀ¯ÇÑ ÆÄÀåÀÇ ºûÀ» ¼±ÅÃÀûÀ¸·Î Èí¼öÇϹǷÎ, Åõ°ú±¤ÀÇ ½ºÆåÆ®·³¿¡´Â ¹°ÁúÀÇ Á¾·ù¿¡ µû¶ó ƯÀ¯ÇÑ ¹è¿­À» °¡Áø Èí¼ö ¼±ÀÌ ³ªÅ¸³­´Ù. µû¶ó¼­, ¾î¶² ¾ç ¶Ç´Â µÎ²²ÀÇ ¼ø¼öÇÑ ¹°ÁúÀÇ Èí¼ö ½ºÆåÆ®·³À» ¸¹ÀÌ °®Ãß°í ÀÖÀ¸¸é, À̰ÍÀ» ±âÃÊ·Î ÇÏ¿© ¹ÌÁö ½Ã·áÀÇ Á¤¼º ºÐ¼®, ¾Ë°í ÀÖ´Â ½Ã·áÀÇ Á¤·® ºÐ¼®, ½Ã·á ¼Ó¿¡ ÀÖ´Â ºÒ¼ø¹°ÀÇ ¹ß°ß ¹× Á¤·®ÇÒ ¼ö ÀÖ´Ù. À̰ÍÀÌ Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ±¤ ºÐ¼®À̸ç, ƯÈ÷ ¿ë¾× ¼Ó¿¡ Á¸ÀçÇÏ´Â ºñŸ¹Î·ùÀÇ Á¤·® µîÀº ÀÌ ¹æ¹ýÀ» »ç¿ëÇÏ¸é ½±°Ô ¾Ë ¼ö ÀÖ´Ù. ºÐ±¤ ºÐ¼®Àº ½ºÆåÆ®·³ ºÐ¼®À̶ó°íµµ Çϴµ¥, ½ºÆåÆ®·³ ºÐ¼®À̶ó°í ÇÒ ¶§´Â ÀÌ»ó°ú °°Àº ºÐ¼® È­Çп¡ÀÇ ÀÀ¿ë ¿Ü¿¡, ¹°ÁúÀÇ ¹æÃâ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¤¹ÐÈ÷ ÃøÁ¤, ÇØ¼®ÇÏ¿© ¹°ÁúÀÇ ¿¡³ÊÁö ÁØÀ§, ÀüÀÌ È®·ü, ºÐÀÚÀÇ °áÇÕ °£°ÝÀ̳ª ºÐÀÚ ±¸Á¶ÀÇ °áÁ¤ µî¿¡µµ ÀÌ¿ëµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
kidney failure, chronic An irreversible and usually progressive reduction in renal function in which both kidneys have been damaged by a variety of diseases to the extent that they are unable to adequately remove the metabolic products from the blood and regulate the body's electrolyte composition and acid-base balance. Chronic kidney failure requires haemodialysis or surgery, usually kidney transplantation.
(12 Dec 1998)
forward heart failure A concept (formerly considered mutually exclusive of backward heart failure) that maintains that the phenomena of congestive heart failure result from the inadequate cardiac output, and especially from the consequent inadequacy of renal blood flow with resulting retention of sodium and water.
Compare: backward heart failure.
(05 Mar 2000)
left-sided heart failure Inability of the left heart to maintain its circulatory load with corresponding rise in pressure in the pulmonary circulation usually with pulmonary congestion and ultimately pulmonary oedema.
(05 Mar 2000)
left ventricular failure <cardiology> A disorder where the left side of the heart fails to pump blood effectively. This results in a back flow (and pressure) and congestion of blood into the lungs. The causes of this condition include, valvular heart disease, cardiomyopathy, anaemia, hyperthyroidism, atrial myxoma, drug toxicity and congenital heart disease. Risk factors include diabetes, alcoholism, obesity and smoking.
Symptoms include increasing shortness of breath with activity and while lying flat. Other symptoms include cough, palpitations, fatigue, decreased urine production and waking in the middle of the nigh with difficulty breathing. Complications include pulmonary oedema, arrhythmias and pleural effusion.
(27 Sep 1997)
liver failure A condition of severe end-stage liver dysfunction that is accompanied by a decline in mental status that may range from confusion (hepatic encephalopathy) to unresponsiveness (hepatic coma). Other features include a mousy odour to the breath, difficulty with balance and walking, tremor and impaired speech.
(27 Sep 1997)
liver failure, acute A form of liver failure with rapid onset. It is often induced by the toxic effect of drugs and various toxic substances in experimental studies in animals and in clinical states in humans. If coma ensues, the constellation of neurological symptoms is referred to as hepatic encephalopathy.
(12 Dec 1998)
low output failure Heart failure in which the cardiac output is subnormal, as is usually seen in failure due to coronary, hypertensive, or valvular heart disease.
(05 Mar 2000)
accumulation analysis A technique in which an intermediate of a metabolic pathway accumulates due to selective inhibition of a particular step in that pathway or in a mutant that is deficient in a certain step. The intermediate is then isolated, analyzed, and identified.
(05 Mar 2000)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
actuarial analysis The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.
(12 Dec 1998)
amino acid analysis Determination and identification of amino acid content of a macromolecule, identification of a specific amino acid in macromolecules, often a mutated protein, identification and quantitation of amino acid content in blood plasma or urine; a key diagnostic aid.
(05 Mar 2000)
analysis <technique> The separation into component parts or elements, the act of determining the component parts of a substance.
Origin: Gr. Lysis = dissolution
(18 Nov 1997)
analysis of variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable.
(12 Dec 1998)
base sequence analysis <molecular biology> A method, sometimes automated, for determining the base sequence.
(09 Oct 1997)
bite analysis A study of the relations of the occlusal surfaces of opposing teeth and their effect upon related structures.
Synonym: bite analysis.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á